Gynaecology Department Institute Clinic of Gynaecology, Obstetrics and Neonatology, Hospital Clinic of Barcelona, Universitat de Barcelona, Barcelona, Spain.
Gynaecology Department Institute Clinic of Gynaecology, Obstetrics and Neonatology, Hospital Clinic of Barcelona, Universitat de Barcelona, Institut d´Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), C/ Villarroel 170, 08036, Barcelona, Spain.
Sci Rep. 2023 Feb 4;13(1):2066. doi: 10.1038/s41598-023-29227-2.
Nowadays, combined oral contraceptives (COCs) are successfully employed for the treatment of endometriosis (END) and adenomyosis (AD) in a large proportion of patients. However, literature focusing on the clinical and sonographic response to treatment in the long-term follow-up of patients with deep endometriosis (DE) and AD is scarce. The aim of this study was to evaluate the changes in the symptoms and the sonographic exams at 12 and 24 months of follow-up in patients who had received a flexible extended COC regimen containing 2 mg of dienogest/30 μg ethinyl estradiol. This prospective, longitudinal, observational study included women diagnosed with DE and AD presenting no surgical indication and were candidates to treatment with COCs. The presence and severity of dysmenorrhea, non-menstrual pelvic pain, deep dyspareunia, dyschezia and dysuria were evaluated using the Numerical Rating Scale (NRS) at baseline, and at 12 and 24 months of treatment. Transvaginal ultrasound was also performed at these check points searching for criteria of AD and reporting the size of the DE nodules and ovarian endometriomas (OE). Sixty-four patients were included. A significant decrease in the number of patients with severe dysmenorrhea and non-menstrual pelvic pain was reported during follow-up. The mean NRS score for dysmenorrhea, non-menstrual pelvic pain, deep dyspareunia, dyschezia and dysuria was also significantly lower at follow-up. There was a significant reduction in the sonographic number and type of AD criteria during follow-up after treatment. Similarly, a significant decrease in the size of OE and uterosacral ligament involvement in DE was observed at the 12-month follow-up, with a further, albeit not statistically significant, decrease in the 12- to 24-month follow-up. Additionally, torus and rectosigmoid DE decreased in size, although the reduction was not statistically significant at any study point. This prospective study suggests a clinical and sonographic improvement after a flexible extended COC regimen in DE and AD patients, which was significant at 12 months of follow-up. The improvement was more evident in AD and OEs compared with DE. Further research with a longer follow-up, larger sample size and comparison with other treatments is needed.
如今,在很大一部分患者中,复方口服避孕药(COC)成功地用于治疗子宫内膜异位症(END)和子宫腺肌病(AD)。然而,关于深部子宫内膜异位症(DE)和 AD 患者长期随访中治疗的临床和超声反应的文献很少。本研究旨在评估接受含有 2 毫克地诺孕素/30 微克炔雌醇的灵活延长 COC 方案治疗的患者在 12 和 24 个月随访时症状和超声检查的变化。这项前瞻性、纵向、观察性研究纳入了诊断为 DE 和 AD 的女性,她们没有手术指征,是 COC 治疗的候选者。使用数字评分量表(NRS)在基线时以及治疗 12 和 24 个月时评估痛经、非经期盆腔痛、深部性交痛、排便困难和排尿困难的存在和严重程度。还在这些检查点进行经阴道超声检查,寻找 AD 的标准,并报告 DE 结节和卵巢子宫内膜异位囊肿(OE)的大小。共纳入 64 例患者。报告称,在随访过程中,严重痛经和非经期盆腔痛患者的数量明显减少。随访时,痛经、非经期盆腔痛、深部性交痛、排便困难和排尿困难的平均 NRS 评分也明显降低。治疗后随访期间,AD 的超声数量和类型标准显著减少。同样,在 12 个月随访时,DE 中 OE 和子宫骶骨韧带受累的大小也观察到显著减少,而在 12 至 24 个月的随访中,虽然没有统计学意义,但进一步减少。此外,DE 的窦道和直肠乙状结肠的大小也有所缩小,尽管在任何研究点都没有统计学意义。这项前瞻性研究表明,在 DE 和 AD 患者中,使用灵活延长的 COC 方案后,临床和超声均有所改善,在 12 个月的随访时具有显著意义。AD 和 OE 的改善比 DE 更明显。需要进一步进行随访时间更长、样本量更大且与其他治疗方法进行比较的研究。